Abstract 1968P
Background
Metastatic Ewing Sarcoma (MES) has a poor prognosis, and therapeutic options are scarce in this rare disease. Large observational studies are needed to improve patients (pts) care and help designing future clinical trials.
Methods
Treatment characteristics, outcomes, and prognostic factors of pts > 12 year-old treated for a MES in 10 French national reference network centers from 2008 to 2018 and included in the prospective database of the French Sarcoma Group were analyzed. The primary objective was to describe treatment modalities of pts with MES in a real-life setting, including systemic treatment (ST) regimen, access to clinical trials (CT) and loco-regional (LR) procedures. Secondary objectives were to assess pts outcome in terms of time to next treatment (TNT), progression free survival (PFS) and overall survival (OS) for each line of ST, as well as the impact of CT access and LR procedures on TNT, PFS and OS in the metastatic setting.
Results
156 pts with MES were included, 80 pts were metastatic from diagnosis, 76 pts had a metastatic relapse. Median follow-up was 76.8 months [66.7; 88.5]. Median age was 21 years (12-86), 44 (28.2%) pts were < 18 year old at metastasis diagnosis. Main primary location was pelvic (34.6%). 147 (94%) pts received ST in the metastatic setting, with a median of 3 lines (IQR 2-5). 102 (65.4%) pts received more than 2 lines. 95 (60.9%) of pts underwent LR procedure for metastasis, including radiation therapy (84.2%), radiological procedures (12.6%) or surgery (8.4%). 30 (31.6%) pts had multiple procedures. Median OS from metastasis diagnosis was 26.6 months [95%CI 21.0; 32.2]. Median TNT was 5.3 months [95%CI 4.9; 5.6] for 1rst line, 5.5 months [95%CI 3.8; 6.8] for 2nd line and 5.5 months [95%CI 3.7; 7.7] and 3.6 months [95%CI 2.5; 4.4] for 3rd and 4rth lines. 66 (44.9%) pts were included in a CT at least once in the metastatic setting, 35 in 1rst line, 28 in 2nd line and 15 and 22 in 3rd and 4rth lines.
Conclusions
This large multicentric observational study details real-world data on patterns of treatments for pts with MES in France. Detailed ST regimens used, median TNT, PFS and OS according to line and ST regimen as well as factors associated with TNT, PFS and OS will be presented at the meeting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Bergonie.
Funding
This study received a funding from Bayer and a grant from INCA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1840P - RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Juliet Carmichael
Session: Poster session 15
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1922P - Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Presenter: Nadia Hindi Muñiz
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15